Evidence map›Paper›PMID 41779341›Full record

Observational studyInternational journal of clinical oncology2026

Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.

Ryosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, Hiroki Yukami, Hiroyuki Uetake, Masahiro Tsuda, Takeshi Suto, Naotoshi Sugimoto, Hitoshi Ojima, Yasumasa Takii and 16 more

Abstract readMulticenter StudyObservational StudyComparative Study
PubMed Publisher
In one paragraph

Observational study in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ryosuke KawagoeDepartment of Gastroenterology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.
Toshikazu MoriwakiDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan. tmoriwak@gmail.com.ORCID http://orcid.org/0000-0001-7702-122X
Kentaro YamazakiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Suntou-gun, Nagaizumi-cho, Shizuoka, 411-8777, Japan.
Hiroki YukamiDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Hiroyuki UetakeDepartment of Clinical Research, National Hospital Organization Disaster Medical Center, 3256 Midori-cho, Tachikawa, 190-0014, Japan.
Masahiro TsudaDepartment of Gastroenterological Oncology, Hyogo Cancer Center, 13-70 Kitaouji-cho, Akashi, 673-8558, Japan.
Takeshi SutoDepartment of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, 1800 Aoyagi, Yamagata, 990-2292, Japan.
Naotoshi SugimotoDepartment of Genetic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
Hitoshi OjimaDepartment of Gastroenterological Surgery, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi-cho, Ota, 373-8550, Japan.
Yasumasa TakiiDepartment of Gastroenterological Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, Niigata, 951-8566, Japan.
Hisateru YasuiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-minami-machi, Chuo-ku, Kobe, 650-0047, Japan.
Masato KomodaDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Yasuhiro ShimadaDivision of Clinical Oncology, Kochi Health Sciences Center, 2125-1 Ike, Kochi, 781-8555, Japan.
Akihito TsujiDepartment of Clinical Oncology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Kita-gun, Miki-cho, Kagawa, 761-0793, Japan.
Toshifumi YamaguchiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, 2-7 Daigaku-machi, Takatsuki, 569-8686, Japan.
Ryoichi SawadaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishi-shinbashi, Minato-ku, Tokyo, 105-8471, Japan.
Katsunori ShinozakiDivision of Clinical Oncology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
Satoshi OtsuDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, 879-5593, Japan.
Kunitoshi ShigeyasuDepartment of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Kenji TsuchihashiDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Takao TamuraDepartment of Medical Oncology, Kindai University Nara Hospital, 1248-1 Otoda-cho, Ikoma, 630-0293, Japan.
Manabu ShiozawaDivision of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Hideki UenoDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, 359-8513, Japan.
Tadamichi DendaDivision of Gastroenterology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba, 260-8717, Japan.
Takahiko ItoDepartment of Gastroenterology, Japan Baptist Hospital, 47 Kitashirakawa-yamanomoto-cho, Sakyo-ku, Kyoto, 606-8273, Japan.
Atsuo TakashimaDivision of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor patients with left-sided metastatic colorectal cancer (mCRC), the recommended first-line treatment is anti-epidermal growth factor receptor (anti-EGFR) antibodies, such as cetuximab or panitumumab, plus doublet chemotherapy. However, the differences in outcomes between cetuximab and panitumumab remain unknown.

methodsClinical data of patients with left-sided all RAS or KRAS wild-type mCRC who received cetuximab or panitumumab plus doublet chemotherapy were retrospectively collected from 24 institutions in Japan. The patients were divided into two groups: the cetuximab and panitumumab groups. Overall survival (OS), progression-free survival (PFS), and response rate (RR) were compared between the two groups.

resultsA total of 233 patients were enrolled: 87 (37.3%) in the cetuximab group and 146 (62.7%) in the panitumumab group. Median OS, PFS, and RR of the cetuximab and panitumumab groups were 26.6 months (95% confidence interval [CI], 19.7-33.4) versus 31.8 months (95% CI, 25.7-37.9), 9.7 months (95% CI, 6.9-12.5) versus 12.4 months (11.1-13.7), and 57.8% versus 71.0%, respectively. In multivariate analysis, OS and RR were significantly better in the panitumumab group than in the cetuximab group (adjusted hazard ratio 0.69, 95% CI 0.50-0.99, p = 0.04; adjusted odds ratio 2.00, 95% CI 1.07-3.73, p = 0.03) and PFS was similar between the two groups (adjusted hazard ratio 0.75, 95% CI 0.55-1.01, p = 0.05).

conclusionAs a first-line treatment for patients with left-sided all RAS or KRAS wild-type mCRC, panitumumab plus doublet chemotherapy may be suggested better efficacy outcomes than cetuximab plus doublet chemotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCetuximabColorectal NeoplasmsPanitumumabAdultAgedAged, 80 and overEast Asian PeopleFemaleHumansJapanMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesCetuximabPanitumumabCetuximabColorectal cancerPanitumumab

Identifiers

PMID41779341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.